Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective.

Authors:
Syed Abbas Raza
Syed Abbas Raza
University of Wisconsin
United States
Ali Jawa
Ali Jawa
Jinnah-Allama Iqbal Institute of Diabetes and Endocrinology
United States
Ibrar Ahmad
Ibrar Ahmad
Rush Medical School
United States
Khalid Mahmud Khan
Khalid Mahmud Khan
Saudi Arabia
Khursheed Khan
Khursheed Khan
Karachi | Pakistan
Nauman Naseer
Nauman Naseer
Westchester Medical Center/New York Medical College

J Pak Med Assoc 2019 Apr;69(4):555-563

National Institute of Cardiovascular Diseases Karachi, Pakistan.

Sodium-glucose co-transporter type 2 inhibitors (SGLT 2- i)are increasingly being used in the management of type 2 diabetes mellitus (T2DM). With the novel insulinindependent glycosuric action, these agents help to attain glycaemic goals by lowering HbA1c and fasting blood glucose. In addition, these agents improve metabolic control in diabetes and ameliorate comorbidities like obesity and hyper tension. Beneficial effec ts on cardiovascular outcomes have been a key attraction for physicians. These agents are used alone or in combination with oral antidiabetic agents and insulin to attain glycaemic and metabolic targets. A major disadvantagewith these agents is the increased risk for genital andurinary infections. When used in appropriate settings, there is no additional increased risk of hypoglycaemia or volume depletion with these agents. Available evidence suggests good efficacy and safety of these agents in diabetes management. The easy and convenient oncedaily dosing should be customized according to patient needs and glycaemic profiles.

Download full-text PDF

Source
April 2019
10 Reads

Publication Analysis

Top Keywords

increased risk
8
attain glycaemic
8
agents
7
control diabetes
4
diabetes ameliorate
4
metabolic control
4
agents evidence
4
depletion agents
4
improve metabolic
4
volume depletion
4
hypoglycaemia volume
4
obesity hyper
4
comorbidities obesity
4
agents improve
4
ameliorate comorbidities
4
evidence suggests
4
risk genital
4
lowering hba1c
4
good efficacy
4
glycaemic goals
4

Similar Publications